The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting
Year: 2019
Type: article
Study design: Observational Study
Abstract: AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c targets in individuals with type 2 diabetes, newly or recently initiated with basal insulin, and the association of hypoglycaemia with target achievement. MATERIALS AND METHODS: A 12-week, prospective, single-arm, observational study of adults with type 2 diabetes, either newly initiated with any basal insulin or start on basal insulin within the preceding 12 months. At enrollment, eligible participants from 28 countries were treated with or without oral antihyperglycaemic drugs and/or GLP-1 receptor agonists. RESULTS: Individualized targets for almost all of the 3139 evaluable participants (99.7%) had been set by their physicians, with 57% of participants having HbA1c targets between 7.0% and <7.5% (53 and <58 mmol/mol). By week 12, 28% and 27% of newly and previously initiated participants, respectively, achieved individualized HbA1c targets with modest average increases in daily insulin dose of 9 and 5 U (0.10 and 0.06 U/kg), respectively, from baseline (14 and 23 U [0.17 and 0.29 U/kg], respectively). Overall, 16% of participants experienced at least one episode of hypoglycaemia. Both the incidence and frequency of hypoglycaemia, but not the severity, were positively associated with a higher likelihood of achieving individualized HbA1c targets (P < 0.05). CONCLUSIONS: In this prospective real-world study, most participants using basal insulin did not achieve the individualized HbA1c targets set by their physicians. Participants who experienced symptomatic hypoglycaemia were more likely to achieve HbA1c targets than those who did not.
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.13673
Authors: Luigi F. Meneghini, Didac Mauricio, Emanuela Orsi, Nebojsa M. Lalic, Anna M.G. Cali, Jukka Westerbacka, Peter Stella, Christophe Candelas, DEA, Valerie Pilorget, Riccardo Perfetti, Kamlesh Khunti, on behalf of the DUNE investigators
Institutions: Parkland Health & Hospital System, The University of Texas Southwestern Medical Center, Hospital de Sant Pau, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Belgrade, Univerzitetski Klinički Centar Srbije, Sanofi (France), Sanofi (United States), University of Leicester
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2914317368
